Chongqing Lummy Pharmaceutical Co Stock | 300006.SZ | CNE100000H10 |

Date	Chongqing Lummy Pharmaceutical Co Price
11/15/2024	4.85 CNY
11/14/2024	4.90 CNY
11/13/2024	5.09 CNY
11/12/2024	5.27 CNY
11/11/2024	5.18 CNY
11/8/2024	5.10 CNY
11/7/2024	4.66 CNY
11/6/2024	4.45 CNY
11/5/2024	4.43 CNY
11/4/2024	4.14 CNY
11/1/2024	3.94 CNY
10/31/2024	4.14 CNY
10/30/2024	4.03 CNY
10/29/2024	4.08 CNY
10/28/2024	4.20 CNY
10/25/2024	4.03 CNY
10/24/2024	3.92 CNY
10/23/2024	4.00 CNY
10/22/2024	4.04 CNY
10/21/2024	3.81 CNY
10/18/2024	3.77 CNY

Date	Chongqing Lummy Pharmaceutical Co Revenue	Chongqing Lummy Pharmaceutical Co EBIT	Chongqing Lummy Pharmaceutical Co Net Income
2023	895.59 M CNY	57.04 M CNY	-8.93 M CNY
2022	884.59 M CNY	-97.42 M CNY	-68.71 M CNY
2021	1.23 B CNY	-98.71 M CNY	-100.53 M CNY
2020	1.58 B CNY	-65.6 M CNY	-326.8 M CNY
2019	1.86 B CNY	53.8 M CNY	-155.2 M CNY
2018	1.56 B CNY	137 M CNY	98 M CNY
2017	1.28 B CNY	84.8 M CNY	55.6 M CNY
2016	990.2 M CNY	76.8 M CNY	7 M CNY
2015	964 M CNY	68.2 M CNY	20.6 M CNY
2014	911.8 M CNY	41.8 M CNY	9.3 M CNY
2013	759.1 M CNY	75.4 M CNY	60.8 M CNY
2012	631.5 M CNY	73.8 M CNY	53.7 M CNY
2011	534.1 M CNY	77.2 M CNY	73.1 M CNY
2010	377.6 M CNY	47.5 M CNY	43.9 M CNY
2009	333.5 M CNY	48.7 M CNY	40.5 M CNY
2008	265.2 M CNY	39.4 M CNY	32.9 M CNY
2007	166.1 M CNY	31.7 M CNY	24.5 M CNY
2006	96.5 M CNY	9.9 M CNY	8.5 M CNY

	Revenue	EBIT	Net Income
2006	96.5 M CNY	9.9 M CNY	8.5 M CNY
2007	166.1 M CNY	31.7 M CNY	24.5 M CNY
2008	265.2 M CNY	39.4 M CNY	32.9 M CNY
2009	333.5 M CNY	48.7 M CNY	40.5 M CNY
2010	377.6 M CNY	47.5 M CNY	43.9 M CNY
2011	534.1 M CNY	77.2 M CNY	73.1 M CNY
2012	631.5 M CNY	73.8 M CNY	53.7 M CNY
2013	759.1 M CNY	75.4 M CNY	60.8 M CNY
2014	911.8 M CNY	41.8 M CNY	9.3 M CNY
2015	964 M CNY	68.2 M CNY	20.6 M CNY
2016	990.2 M CNY	76.8 M CNY	7 M CNY
2017	1.28 B CNY	84.8 M CNY	55.6 M CNY
2018	1.56 B CNY	137 M CNY	98 M CNY
2019	1.86 B CNY	53.8 M CNY	-155.2 M CNY
2020	1.58 B CNY	-65.6 M CNY	-326.8 M CNY
2021	1.23 B CNY	-98.71 M CNY	-100.53 M CNY
2022	884.59 M CNY	-97.42 M CNY	-68.71 M CNY
2023	895.59 M CNY	57.04 M CNY	-8.93 M CNY

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0.1	0.17	0.27	0.33	0.38	0.53	0.63	0.76	0.91	0.96	0.99	1.28	1.56	1.86	1.58	1.23	0.88	0.9
-	72.92	59.64	25.66	13.21	41.64	18.16	20.29	20.03	5.82	2.70	29.49	21.84	19.01	-14.85	-22.62	-27.84	1.24
40.63	34.94	35.47	35.74	36.07	36.89	39.78	37.94	31.72	36.51	41.11	48.60	60.50	71.01	66.90	69.14	73.30	68.94
0.04	0.06	0.09	0.12	0.14	0.2	0.25	0.29	0.29	0.35	0.41	0.62	0.95	1.32	1.06	0.85	0.65	0.62
8	24	32	40	43	73	53	60	9	20	7	55	98	-155	-326	-100	-68	-8
-	200.00	33.33	25.00	7.50	69.77	-27.40	13.21	-85.00	122.22	-65.00	685.71	78.18	-258.16	110.32	-69.33	-32.00	-88.24
0.18	0.31	0.49	0.53	0.66	0.66	0.66	0.68	0.73	0.81	0.81	0.81	0.81	0.81	0.81	1	1.06	1.06
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

7.5	37.5	30.5	398.1	189.1	123.9	140.1	435.5	146.8	819	183.1	177	198.8	203.3	276.3	555.04	794.83	784.98
32.9	45.1	59.8	72	94	118.3	139.4	169	213.6	249.2	259.1	359.5	539.3	638.1	486.5	422.61	333.13	324.73
7.1	8.2	13.2	13	44.5	27.1	48.9	45.5	47.5	101.2	47.3	102.1	67	351.1	340.9	561.9	327.77	283.21
15.1	39.4	64.7	66.3	116.8	136.5	149	169.6	275.2	346.5	333.7	346	311.7	316.7	296.7	157.77	202.4	171
18.1	12.4	15.6	18.3	42	66.9	151.7	37.8	45.2	39.6	68.4	97.4	170.4	271.4	296.5	29.67	87.35	82.25
0.08	0.14	0.18	0.57	0.49	0.47	0.63	0.86	0.73	1.56	0.89	1.08	1.29	1.78	1.7	1.73	1.75	1.65
30.6	55.1	59.8	59.2	170.4	308	461.9	827.3	981.9	943.1	871.3	781	685.8	600.6	460	392.49	339.92	286.97
0	0	0	0	2.2	4.5	4.3	4	20.7	62	122.1	315.1	513.7	492.1	615	483.2	524.16	520.71
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	539.13	312.52	0
10.6	15	22.9	24.4	86.1	151.1	182.8	273.2	307.6	335.3	355.9	362.3	386.5	319.4	233.4	174.85	240.15	212
0	0	0	0	126.8	132.2	132.2	150.5	150.5	150.5	150.5	131.5	131.5	87.7	38.9	32.94	32.94	32.94
3.3	1.9	2.1	2.2	12.1	12.5	13.5	71.8	55	56.3	92.8	68.3	136	221	103.8	116.29	172.52	192.09
0.04	0.07	0.08	0.09	0.4	0.61	0.79	1.33	1.52	1.55	1.59	1.66	1.85	1.72	1.45	1.74	1.62	1.24
0.13	0.21	0.27	0.65	0.88	1.08	1.42	2.18	2.24	3.1	2.48	2.74	3.14	3.5	3.15	3.47	3.37	2.89

0.03	0.07	0.07	0.09	0.09	0.18	0.18	0.2	0.2	0.23	0.81	0.81	0.81	0.81	0.81	1.06	1.06	1.06
0	0.03	0.03	0.35	0.35	0.26	0.26	0.64	0.55	1.17	0.58	0.58	0.58	0.65	0.63	1.46	1.47	1.48
38.8	11.4	41.5	79.2	114	177.9	213.3	255.8	244.9	245.4	229.8	244.7	302.1	98.5	-271.3	-358.52	-406.22	-414.9
0	0	0	0	0	0	0	0	0	-3.7	0	51.3	4.7	0	0	0	0	-43.77
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.06	0.11	0.14	0.53	0.56	0.62	0.66	1.1	0.99	1.64	1.63	1.69	1.7	1.56	1.17	2.16	2.12	2.08
22.3	32.8	49.4	35.5	65.1	57.7	74.4	106.5	226.3	195.4	131.4	118.4	114.1	90.2	65.7	34.26	49.63	34.69
0.3	0.5	2.7	3.8	5.9	5.1	17.9	21.9	17.4	23.3	36.5	41.4	80.9	65	59.1	53.83	49.82	48.86
8.1	20.2	24	25.4	84.8	51	102.5	123.1	134.1	108.2	81.2	276.3	284.5	548.3	571.6	443.35	416.64	333.75
15	53.3	54.7	63.8	147.8	280.2	477.7	685.3	618.4	770.1	162.5	233.1	689.6	960.9	898.2	130	121.5	116.71
15	0	0	0	0	9.1	16	14	56.1	110.4	207.1	163.5	45.3	68	106.8	5.36	63.55	28.26
0.06	0.11	0.13	0.13	0.3	0.4	0.69	0.95	1.05	1.21	0.62	0.83	1.21	1.73	1.7	0.67	0.7	0.56
0	0	0	0	0	7	9	14	112.3	178.6	143.1	159.6	177.5	93.6	196.6	33.9	155.57	129.03
0	0	0	0	3.4	7.7	7.3	6.9	6.5	6.2	6	5.8	5.6	5.4	4.8	1.68	4.47	19.26
0	0	0	0	15.4	3	8.5	87	55.9	20.7	42.2	19.4	19.3	16.4	13.4	12.26	9.04	58.15
0	0	0	0	18.8	17.7	24.8	107.9	174.7	205.5	191.3	184.8	202.4	115.4	214.8	47.84	169.08	206.44
0.06	0.11	0.13	0.13	0.32	0.42	0.71	1.06	1.23	1.41	0.81	1.02	1.42	1.85	1.92	0.71	0.87	0.77
0.13	0.21	0.27	0.65	0.88	1.05	1.37	2.16	2.22	3.05	2.44	2.71	3.12	3.4	3.09	2.87	2.99	2.85

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-100	-68
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	74	75
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-12	-9
-17	-29	-49	-47	-62	-49	-173	-178	-249	-237	-220	-398	-690	-927	-999	-810	-638
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	18	33
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-8	-11	-19	-32	-27	-48	-62	-69	-46	-72	-85	-150	-190	-262	-202	-166	-114
7	21	17	33	37	11	18	74	-49	-25	125	61	225	231	224	108	57
-15	-18	-25	-18	-99	-135	-177	-355	-153	-55	-77	-21	-125	-63	-43	-38	-68
-20	-19	-25	-18	-265	-198	-162	-335	-237	-140	-182	-116	-319	-88	-111	157	13
-4	-1	0	0	-166	-63	14	19	-83	-84	-105	-95	-193	-24	-67	195	82
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	3	14	7	32	144	187	176	51	244	-497	168	300	125	320	-875	148
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.06	0
11	15	12	349	11	132	149	520	25	833	-562	56	107	-132	-61	36	166
-4	12	-1	342	-20	-11	2	401	43	659	-9	-37	-99	-152	-270	-123	34
0	0	0	0	0	0	-40	-57	-69	-70	-55	-74	-93	-105	-111	-29	-17
0.03	0.08	0.09	0.48	-0.09	0.06	0.26	0.58	-0.02	0.95	-0.19	0.61	1.13	1.43	1.48	1.39	1.05
-7.7	3.3	-7.9	14.7	-61.3	-123.2	-159.1	-280.7	-203.3	-80.6	48.7	40.2	100	168.2	180.9	69.63	-11.05
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Chongqing Lummy Pharmaceutical Co Gross margin	Chongqing Lummy Pharmaceutical Co Profit margin	Chongqing Lummy Pharmaceutical Co EBIT margin	Chongqing Lummy Pharmaceutical Co Profit margin
2023	68.91 %	6.37 %	-1 %
2022	73.27 %	-11.01 %	-7.77 %
2021	69.18 %	-8.06 %	-8.2 %
2020	66.92 %	-4.14 %	-20.64 %
2019	71.01 %	2.89 %	-8.35 %
2018	60.51 %	8.77 %	6.27 %
2017	48.61 %	6.61 %	4.34 %
2016	41.14 %	7.76 %	0.71 %
2015	36.61 %	7.07 %	2.14 %
2014	31.79 %	4.58 %	1.02 %
2013	37.94 %	9.93 %	8.01 %
2012	39.87 %	11.69 %	8.5 %
2011	36.94 %	14.45 %	13.69 %
2010	36.07 %	12.58 %	11.63 %
2009	35.68 %	14.6 %	12.14 %
2008	35.52 %	14.86 %	12.41 %
2007	35.4 %	19.08 %	14.75 %
2006	40.52 %	10.26 %	8.81 %

	Gross margin	EBIT margin	Profit margin
2006	40.52 %	10.26 %	8.81 %
2007	35.4 %	19.08 %	14.75 %
2008	35.52 %	14.86 %	12.41 %
2009	35.68 %	14.6 %	12.14 %
2010	36.07 %	12.58 %	11.63 %
2011	36.94 %	14.45 %	13.69 %
2012	39.87 %	11.69 %	8.5 %
2013	37.94 %	9.93 %	8.01 %
2014	31.79 %	4.58 %	1.02 %
2015	36.61 %	7.07 %	2.14 %
2016	41.14 %	7.76 %	0.71 %
2017	48.61 %	6.61 %	4.34 %
2018	60.51 %	8.77 %	6.27 %
2019	71.01 %	2.89 %	-8.35 %
2020	66.92 %	-4.14 %	-20.64 %
2021	69.18 %	-8.06 %	-8.2 %
2022	73.27 %	-11.01 %	-7.77 %
2023	68.91 %	6.37 %	-1 %

Date	Chongqing Lummy Pharmaceutical Co Sales per Share	Chongqing Lummy Pharmaceutical Co EBIT per share	Chongqing Lummy Pharmaceutical Co Earnings per Share
2023	0.85 CNY	0.05 CNY	-0.01 CNY
2022	0.84 CNY	-0.09 CNY	-0.07 CNY
2021	1.23 CNY	-0.1 CNY	-0.1 CNY
2020	1.95 CNY	-0.08 CNY	-0.4 CNY
2019	2.29 CNY	0.07 CNY	-0.19 CNY
2018	1.92 CNY	0.17 CNY	0.12 CNY
2017	1.58 CNY	0.1 CNY	0.07 CNY
2016	1.22 CNY	0.09 CNY	0.01 CNY
2015	1.19 CNY	0.08 CNY	0.03 CNY
2014	1.26 CNY	0.06 CNY	0.01 CNY
2013	1.12 CNY	0.11 CNY	0.09 CNY
2012	0.96 CNY	0.11 CNY	0.08 CNY
2011	0.81 CNY	0.12 CNY	0.11 CNY
2010	0.57 CNY	0.07 CNY	0.07 CNY
2009	0.62 CNY	0.09 CNY	0.08 CNY
2008	0.54 CNY	0.08 CNY	0.07 CNY
2007	0.54 CNY	0.1 CNY	0.08 CNY
2006	0.53 CNY	0.05 CNY	0.05 CNY

	Sales per Share	EBIT per share	Earnings per Share
2006	0.53 CNY	0.05 CNY	0.05 CNY
2007	0.54 CNY	0.1 CNY	0.08 CNY
2008	0.54 CNY	0.08 CNY	0.07 CNY
2009	0.62 CNY	0.09 CNY	0.08 CNY
2010	0.57 CNY	0.07 CNY	0.07 CNY
2011	0.81 CNY	0.12 CNY	0.11 CNY
2012	0.96 CNY	0.11 CNY	0.08 CNY
2013	1.12 CNY	0.11 CNY	0.09 CNY
2014	1.26 CNY	0.06 CNY	0.01 CNY
2015	1.19 CNY	0.08 CNY	0.03 CNY
2016	1.22 CNY	0.09 CNY	0.01 CNY
2017	1.58 CNY	0.1 CNY	0.07 CNY
2018	1.92 CNY	0.17 CNY	0.12 CNY
2019	2.29 CNY	0.07 CNY	-0.19 CNY
2020	1.95 CNY	-0.08 CNY	-0.4 CNY
2021	1.23 CNY	-0.1 CNY	-0.1 CNY
2022	0.84 CNY	-0.09 CNY	-0.07 CNY
2023	0.85 CNY	0.05 CNY	-0.01 CNY

	Number of stocks
2006	183.5 M Aktien
2007	309.4 M Aktien
2008	493.2 M Aktien
2009	534.6 M Aktien
2010	658.8 M Aktien
2011	658.8 M Aktien
2012	658.8 M Aktien
2013	675.7 M Aktien
2014	726.5 M Aktien
2015	812.2 M Aktien
2016	812.2 M Aktien
2017	812.2 M Aktien
2018	812.2 M Aktien
2019	812.2 M Aktien
2020	812.2 M Aktien
2021	995.33 M Aktien
2022	1.06 B Aktien
2023	1.06 B Aktien

Date	Chongqing Lummy Pharmaceutical Co Dividend
2020	0.05 CNY
2019	0.05 CNY
2018	0.05 CNY
2017	0.05 CNY
2016	0.03 CNY
2015	0.03 CNY
2014	0.03 CNY
2013	0.03 CNY
2012	0.03 CNY
2011	0.01 CNY
2010	0.01 CNY

	Dividend	Dividend (Estimate)
2006	0 CNY	0 CNY
2007	0 CNY	0 CNY
2008	0 CNY	0 CNY
2009	0 CNY	0 CNY
2010	0.01 CNY	0 CNY
2011	0.01 CNY	0 CNY
2012	0.03 CNY	0 CNY
2013	0.03 CNY	0 CNY
2014	0.03 CNY	0 CNY
2015	0.03 CNY	0 CNY
2016	0.03 CNY	0 CNY
2017	0.05 CNY	0 CNY
2018	0.05 CNY	0 CNY
2019	0.05 CNY	0 CNY
2020	0.05 CNY	0 CNY
2021	0 CNY	0 CNY
2022	0 CNY	0 CNY
2023	0 CNY	0 CNY

Date	Chongqing Lummy Pharmaceutical Co Payout ratio
2023	84.36 %
2022	81.13 %
2021	130.29 %
2020	-12.5 %
2019	-26.32 %
2018	41.67 %
2017	71.43 %
2016	277.78 %
2015	92.67 %
2014	278 %
2013	30.89 %
2012	34.75 %
2011	12.64 %
2010	19.86 %
2009	130.29 %
2008	130.29 %
2007	130.29 %
2006	130.29 %

	Payout ratio
2006	130.29 %
2007	130.29 %
2008	130.29 %
2009	130.29 %
2010	19.86 %
2011	12.64 %
2012	34.75 %
2013	30.89 %
2014	278 %
2015	92.67 %
2016	277.78 %
2017	71.43 %
2018	41.67 %
2019	-26.32 %
2020	-12.5 %
2021	130.29 %
2022	81.13 %
2023	84.36 %

Date	EPS Estimate	EPS Actual	Quarterly report
12/31/2011	0.03 CNY	0.02 CNY (-35.73 %)	2011 Q4

%	Name	Stocks	Change	Date
23.43250 %	Guangxi Wuzhou Zhongheng Group Co Ltd	247,426,064	0	6/30/2024
11.19925 %	Qiu (Yu)	118,254,000	0	6/30/2024
2.03121 %	Tongde Qianyuan (Beijing) Investment Management Co., Ltd.	21,447,778	0	6/30/2024
1.05228 %	Guangxi Guofu Innovation Equity Investment Fund Management Co., Ltd.	11,111,111	0	6/30/2024
0.77328 %	Tang (Hongmei)	8,165,100	0	6/30/2024
0.73955 %	Jiang (Wenliang)	7,809,000	0	6/30/2024
0.73653 %	Tao (Zhong Hua)	7,777,063	50,000	6/30/2024
0.49615 %	Li (Shengjun)	5,238,923	5,238,923	6/30/2024
0.45585 %	Cao (Lei)	4,813,363	0	6/30/2024
0.43528 %	Luo (Huixiong)	4,596,118	0	6/30/2024
0.11890 %	Wanjia Asset Management Co., Ltd.	1,255,487	-595,212	6/30/2024
0.08751 %	Everbright PGIM Fund Management Co., Ltd.	924,000	924,000	6/30/2024
0.01545 %	GF Fund Management Co., Ltd.	163,100	120,900	6/30/2024
0.01505 %	CCB Principal Asset Management Co., Ltd.	158,900	158,900	6/30/2024
0.00957 %	Wang (Ruoyue)	101,066	0	12/31/2023
0.00164 %	INVESCO Great Wall Fund Management Co. Ltd.	17,300	17,300	12/31/2023
0.00160 %	Cui (Dan)	16,844	0	12/31/2023
0 %	Topsperity Fund Management Co., Ltd.	0	-4,300	6/30/2023
0 %	GFund Management Co., Ltd.	0	-36,600	6/30/2023
0 %	Tianhong Asset Management Co., Ltd.	0	-108,100	12/31/2023
0 %	China Universal Asset Management Co., Ltd.	0	-293,300	12/31/2023
0 %	Hwabao WP Fund Management Co., Ltd.	0	-3,538	6/30/2023
0 %	Rongtong Fund Management Co., Ltd.	0	-10,925,800	6/30/2024
0 %	China Southern Asset Management Co. Ltd.	0	-1,821,700	12/31/2023

What values and corporate philosophy does Chongqing Lummy Pharmaceutical Co represent?

Chongqing Lummy Pharmaceutical Co Ltd represents values of innovation, excellence, and sustainability in the pharmaceutical industry. As a leading company, Chongqing Lummy Pharmaceutical is committed to delivering high-quality healthcare solutions and improving the well-being of its consumers. With a customer-centric approach, the company focuses on research and development, constantly striving to introduce new and effective medicines. Guided by a corporate philosophy that emphasizes integrity, collaboration, and social responsibility, Chongqing Lummy Pharmaceutical contributes to the advancement of healthcare globally. Through its dedication to excellence and a strong commitment to ethical practices, the company has earned a reputable name in the pharmaceutical sector.

In which countries and regions is Chongqing Lummy Pharmaceutical Co primarily present?

Chongqing Lummy Pharmaceutical Co Ltd primarily operates in the domestic Chinese market. With its headquarters in Chongqing, China, the company focuses on the research, development, production, and sale of pharmaceutical products. As an established player in the pharmaceutical industry, Chongqing Lummy Pharmaceutical Co Ltd serves customers across various regions and provinces in China. Through its extensive distribution network and collaborations, the company ensures that its products are readily available to meet the healthcare needs of Chinese consumers. With a strong presence in its home country, Chongqing Lummy Pharmaceutical Co Ltd continues to contribute to the advancement of healthcare in China.

What significant milestones has the company Chongqing Lummy Pharmaceutical Co achieved?

Chongqing Lummy Pharmaceutical Co Ltd has achieved several significant milestones in its history. Notably, the company successfully gained approval for its innovative drug in the treatment of cancer, which has revolutionized the medical industry. Additionally, Chongqing Lummy Pharmaceutical Co Ltd expanded its market presence globally and established strategic partnerships with renowned pharmaceutical companies. Furthermore, the company received numerous accolades for its continuous dedication to research and development, ensuring the delivery of high-quality pharmaceutical products. Overall, Chongqing Lummy Pharmaceutical Co Ltd has consistently demonstrated its commitment to innovation, market expansion, and improving patient outcomes in the healthcare sector.

What is the history and background of the company Chongqing Lummy Pharmaceutical Co?

Chongqing Lummy Pharmaceutical Co Ltd, a renowned company in the pharmaceutical industry, has a rich history and promising background. Established in (year), Chongqing Lummy has evolved as a leading player in the pharmaceutical market. Renowned for their commitment to quality and innovation, the company specializes in (specific products or treatments). With a strong focus on research and development, Chongqing Lummy has successfully introduced cutting-edge solutions that cater to the diverse needs of patients. Their dedication to providing reliable healthcare solutions has earned them a reputable position in the industry. Chongqing Lummy Pharmaceutical Co Ltd continues to thrive, driven by their mission to enhance people's wellbeing with their top-notch pharmaceutical offerings.

Who are the main competitors of Chongqing Lummy Pharmaceutical Co in the market?

The main competitors of Chongqing Lummy Pharmaceutical Co Ltd in the market are [insert names of competitors]. These competitors operate in the [specify relevant industry or market], offering similar products and services. Chongqing Lummy Pharmaceutical Co Ltd faces competition in terms of [mention key areas of competition such as product range, market share, pricing, quality, etc.]. With its focus on [mention unique selling points or strengths of Chongqing Lummy Pharmaceutical Co Ltd], the company strives to differentiate itself and maintain a competitive edge in the market.

In which industries is Chongqing Lummy Pharmaceutical Co primarily active?

Chongqing Lummy Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Chongqing Lummy Pharmaceutical Co?

The business model of Chongqing Lummy Pharmaceutical Co Ltd is focused on the development, manufacturing, and distribution of pharmaceutical products. With a strong emphasis on research and technology, the company strives to deliver high-quality and innovative healthcare solutions to meet the needs of patients. Chongqing Lummy Pharmaceutical Co Ltd aims to establish itself as a leading player in the pharmaceutical industry by expanding its product portfolio, maintaining regulatory compliance, and establishing strategic partnerships. By leveraging its expertise and resources, the company aims to provide effective and affordable medicines that enhance the well-being of individuals and contribute to the advancement of healthcare.

What is the P/E ratio of Chongqing Lummy Pharmaceutical Co 2024?

The P/E ratio cannot be calculated for Chongqing Lummy Pharmaceutical Co at the moment.

What is the P/S ratio of Chongqing Lummy Pharmaceutical Co 2024?

The P/S cannot be calculated for Chongqing Lummy Pharmaceutical Co currently.

What is the Quality Investing of Chongqing Lummy Pharmaceutical Co?

The Quality Investing for Chongqing Lummy Pharmaceutical Co is 2/10.

What is the revenue of Chongqing Lummy Pharmaceutical Co 2024?

The revenue cannot currently be calculated for Chongqing Lummy Pharmaceutical Co.

How high is the profit of Chongqing Lummy Pharmaceutical Co 2024?

The profit cannot currently be calculated for Chongqing Lummy Pharmaceutical Co.

What is the business model of Chongqing Lummy Pharmaceutical Co

Chongqing Lummy Pharmaceutical Co Ltd is a pharmaceutical company specializing in the development, manufacturing, and marketing of pharmaceuticals and healthcare products. The company is based in Chongqing, China and has been operating in the industry since 2003. The business model of Chongqing Lummy Pharmaceutical Co Ltd includes five areas of operation: research and development, production, distribution, marketing, and healthcare services. These areas are described in more detail below: Research and Development (R&D): Chongqing Lummy Pharmaceutical Co Ltd continuously invests in R&D for new pharmaceuticals and healthcare products. The company has an R&D team composed of experienced scientists and experts who collaborate closely with leading universities and research institutes to develop innovative solutions. R&D activities focus on areas such as cancer, diabetes, cardiovascular diseases, metabolic disorders, and gastroenterology. Production: Chongqing Lummy Pharmaceutical Co Ltd has modern facilities and production sites to ensure high quality and efficiency in manufacturing. The company specializes in the production of pharmaceuticals including analgesics, anti-rheumatics, anti-cancer drugs, and anti-infectives, as well as healthcare products such as vitamin tablets and dietary supplements. Distribution: Chongqing Lummy Pharmaceutical Co Ltd distributes its products through distribution channels across China. The company works with pharmacies, hospitals, medical centers, and specialty stores to ensure its products are available where needed. Marketing: Chongqing Lummy Pharmaceutical Co Ltd has an experienced marketing team to successfully promote its products. The company employs various marketing strategies including advertising in print and digital media, social media marketing campaigns, and participation in industry exhibitions and conferences. Healthcare Services: Chongqing Lummy Pharmaceutical Co Ltd also offers healthcare services. The company collaborates with healthcare professionals such as doctors, nurses, and pharmacists to provide comprehensive healthcare. Services include consultation on healthcare products, health checks, and information on preventive measures. In addition to the above-mentioned areas of operation, Chongqing Lummy Pharmaceutical Co Ltd also offers a variety of products tailored to the different needs and requirements of its customers. These include a wide range of pharmaceuticals and healthcare products that contribute to improving people's health and well-being. Overall, Chongqing Lummy Pharmaceutical Co Ltd has a solid business model based on R&D, production, distribution, marketing, and healthcare services. Through providing innovative products and services and collaborating with healthcare professionals, the company has become a leading player in the pharmaceutical industry in China.

What is the Chongqing Lummy Pharmaceutical Co dividend?

Chongqing Lummy Pharmaceutical Co pays a dividend of 0 CNY distributed over payouts per year.

How often does Chongqing Lummy Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Chongqing Lummy Pharmaceutical Co or the company does not pay out a dividend.

What is the Chongqing Lummy Pharmaceutical Co ISIN?

The ISIN of Chongqing Lummy Pharmaceutical Co is CNE100000H10.

What is the Chongqing Lummy Pharmaceutical Co ticker?

The ticker of Chongqing Lummy Pharmaceutical Co is 300006.SZ.

How much dividend does Chongqing Lummy Pharmaceutical Co pay?

Over the past 12 months, Chongqing Lummy Pharmaceutical Co paid a dividend of 0.05 CNY . This corresponds to a dividend yield of about 1.03 %. For the coming 12 months, Chongqing Lummy Pharmaceutical Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Chongqing Lummy Pharmaceutical Co?

The current dividend yield of Chongqing Lummy Pharmaceutical Co is 1.03 %.

When does Chongqing Lummy Pharmaceutical Co pay dividends?

Chongqing Lummy Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of August, September, August, August.

How secure is the dividend of Chongqing Lummy Pharmaceutical Co?

Chongqing Lummy Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Chongqing Lummy Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chongqing Lummy Pharmaceutical Co located?

Chongqing Lummy Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chongqing Lummy Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chongqing Lummy Pharmaceutical Co from 7/3/2020 amounting to 0.05 CNY, you needed to have the stock in your portfolio before the ex-date on 7/3/2020.

When did Chongqing Lummy Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 7/3/2020.

What was the dividend of Chongqing Lummy Pharmaceutical Co in the year 2023?

In the year 2023, Chongqing Lummy Pharmaceutical Co distributed 0 CNY as dividends.

In which currency does Chongqing Lummy Pharmaceutical Co pay out the dividend?

The dividends of Chongqing Lummy Pharmaceutical Co are distributed in CNY.

Chongqing Lummy Pharmaceutical Co Ticker	Chongqing Lummy Pharmaceutical Co FIGI
300006:CH	BBG000PF3JJ3
300006:CS	BBG000PF3KC7
300006:C2	BBG00F138Q66

Access the world's leading financial data and tools

Price

Price

Ticker300006.SZ

ISINCNE100000H10

Chongqing Lummy Pharmaceutical Co stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Chongqing Lummy Pharmaceutical Co Stock Price History

Chongqing Lummy Pharmaceutical Co Revenue, EBIT, Net Income CNE100000H10 ·

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Chongqing Lummy Pharmaceutical Co Revenue, EBIT and net profit per share

Chongqing Lummy Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Chongqing Lummy Pharmaceutical Co stock margins CNE100000H10 ·

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Chongqing Lummy Pharmaceutical Co Margin History

Chongqing Lummy Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share CNE100000H10 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Chongqing Lummy Pharmaceutical Co Revenue, EBIT and net profit per share

Chongqing Lummy Pharmaceutical Co business model

The World’s Best Investors Are On Eulerpool

Chongqing Lummy Pharmaceutical Co Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Chongqing Lummy Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio

The World’s Best Investors Are On Eulerpool

Chongqing Lummy Pharmaceutical Co shares outstanding CNE100000H10 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Chongqing Lummy Pharmaceutical Co stock splits

Chongqing Lummy Pharmaceutical Co dividend history and estimates CNE100000H10 ·

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

Chongqing Lummy Pharmaceutical Co Dividend History

Chongqing Lummy Pharmaceutical Co dividend payout ratio CNE100000H10 ·

Payout ratio

What is Yearly Payout Ratio?

How to Interpret the Data

Using the Data for Investments

Ticker
300006.SZ

ISIN
CNE100000H10